Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors. uri icon

authors

  • Tsimberidou, Apostolia M
  • Tweardy, David J
  • Kaseb, Ahmed O
  • Vining, David J
  • Arora, Sukeshi P
  • de Achaval, Sofia
  • Larson, Jeffrey
  • Kauh, John
  • Cartwright, Carrie
  • Avritscher, Rony
  • Alibhai, Imran

publication date

  • March 17, 2025